Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Filings indexed 1,576 across all filing types
Latest filing 2024-11-08 Director's Dealing
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-11-08 English
Director's Dealing 2024
Director's Dealing
2024-11-08 English
Director's Dealing 2024
Director's Dealing
2024-11-08 English
Director's Dealing 2024
Director's Dealing
2024-11-08 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2024
2024-11-07 English
An additional payment was received due to an agreement with Silex
Capital/Financing Update Classification · 99% confidence The document explicitly states it is a "FORM 8-K" and a "CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934". Form 8-K is used to announce major events that shareholders should know about between quarterly or annual reports. None of the provided specific codes (10-K, IR, ER, etc.) directly map to Form 8-K. However, Form 8-K filings often contain material updates that might fall under 'Other Events' (Item 8.01 in this case), which could relate to financing (CAP) or other material changes. Since Form 8-K is a general current report mandated by the SEC, and there is no specific 'Form 8-K' code, the most appropriate fallback category for a general, material, unscheduled SEC filing that doesn't fit the other specific categories (like dividend, management change, or earnings) is 'Regulatory Filings' (RNS). The document is a full report, not just an announcement of a report, so RPA is not appropriate.
2024-10-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.